Veruprevir

Veruprevir - an orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis c virus (hcv) protease complex comprised of non-structural protein 3 and 4a (ns3/ns4a), with potential activity against hcv genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the hcv ns3/ns4a protease and prevents ns3/ns4a protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in hcv genotype 1-infected host cells. Ns3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the hcv polyprotein and plays a key role during hcv ribonucleic acid (rna) replication. Ns4a is an activating factor for ns3. Hcv is a small, enveloped, single-stranded rna virus belonging to the flaviviridae family, and infection is associated with the development of hepatocellular carcinoma (hcc). See paritaprevir